The Placebo effect does not last past 6 months, the deterioration of Parkinsons continues and is recognisable. The UPDRS, Unified Parkinson's Disease Rating Scale, which is much more complicated will identify the continued advance of Parkinsons on an individual.
My initial concern was that a single individual tester would have to assess the trial patients because there could be interpretation of "Better" or "Improvement" . any concern has been alleviated as the UPDR scale is comprehensive and designed specifically for clinicians to be able to gauge Parkinsons Patients on a Global common Platform.
Also I believe LCT have utilised a single testing clinician from beginning to end.
Big trade in the States last night and whats more important "no one is shorting LCT" so the traders think its up , up and away.
phase II Vs phase I, page-34
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.81M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.7¢ | 0.6¢ | $7.007K | 1.008M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 2864983 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 2187552 | 7 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |